Literature DB >> 19609201

A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.

For Yue Tso1, Federico G Hoffmann, Damien C Tully, Philippe Lemey, Robert A Rasmussen, Hong Zhang, Ruth M Ruprecht, Charles Wood.   

Abstract

OBJECTIVE: To evaluate whether HIV-1 clade C (HIV-C) envelope variations that arise during disease progression in rhesus macaque model reflect changes that occur naturally in human infection.
DESIGN: An infant macaque was infected with SHIV-1157i, an R5 tropic clade C SHIV, that expresses a primary HIV-C envelope derived from an infected human infant and monitored over a 5-year period. Genetic variation of the V1-V5 envelope region, which is the main target for humoral immune responses, derived from the infected macaque and infant was examined.
METHODS: The V1-V5 envelope region was cloned and sequenced from longitudinal peripheral blood mononuclear cell samples collected from the infected macaque and infant. Phylogenetic analysis [phylogenetic tree, diversity, divergence, ratio of nonsynonymous (dN) and synonymous substitution (dS) and dN distribution] was performed. Plasma RNA viral load, CD4(+) T-cell count, changes in the length of V1-V5 region, putative N-linked glycosylation site number and distribution were also measured.
RESULTS: Phylogenetic analysis revealed that changes in the macaque closely reflected those of the infant during disease progression. Similar distribution patterns of dN and hot spots were observed between the macaque and infant. Analysis of putative N-linked glycosylation sites revealed several common variations between the virus populations in the two host species. These variations correlate with decline of CD4 T-cell count in the macaque and might be linked with disease progression.
CONCLUSION: SHIV-C infection of macaque is a relevant animal model for studying variation of primary HIV-C envelope during disease progression and could be used to analyze the selection pressures that are associated with those changes. 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609201      PMCID: PMC2901162          DOI: 10.1097/QAD.0b013e32832f3da6

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  58 in total

1.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

2.  Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration.

Authors:  Howard A Ross; Allen G Rodrigo
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease.

Authors:  F Salvatori; S Masiero; C Giaquinto; C M Wade; A J Brown; L Chieco-Bianchi; A De Rossi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

5.  Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.

Authors:  Regina Hofmann-Lehmann; Josef Vlasak; Agnès-Laurence Chenine; Pei-Lin Li; Timothy W Baba; David C Montefiori; Harold M McClure; Daniel C Anderson; Ruth M Ruprecht
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.

Authors:  M S Fung; C R Sun; W L Gordon; R S Liou; T W Chang; W N Sun; E S Daar; D D Ho
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals.

Authors:  Jennifer L Greenier; Koen K A Van Rompay; David Montefiori; Patricia Earl; Bernard Moss; Marta L Marthas
Journal:  Virol J       Date:  2005-02-14       Impact factor: 4.099

View more
  6 in total

1.  Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants.

Authors:  Hong Zhang; Damien C Tully; Federico G Hoffmann; Jun He; Chipepo Kankasa; Charles Wood
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

2.  Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms.

Authors:  Lucie Etienne; Eric Nerrienet; Matthew LeBreton; Godwin Tafon Bibila; Yacouba Foupouapouognigni; Dominique Rousset; Ahmadou Nana; Cyrille F Djoko; Ubald Tamoufe; Avelin F Aghokeng; Eitel Mpoudi-Ngole; Eric Delaporte; Martine Peeters; Nathan D Wolfe; Ahidjo Ayouba
Journal:  Retrovirology       Date:  2011-01-13       Impact factor: 4.602

Review 3.  Coreceptor use in nonhuman primate models of HIV infection.

Authors:  Silvana Tasca Sina; Wuze Ren; Cecilia Cheng-Mayer
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

4.  Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing.

Authors:  For Yue Tso; Damien C Tully; Sandra Gonzalez; Christopher Quince; On Ho; Patricia Polacino; Ruth M Ruprecht; Shiu-Lok Hu; Charles Wood
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

5.  Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.

Authors:  For Yue Tso; Levon Abrahamyan; Shiu-Lok Hu; Ruth M Ruprecht; Charles Wood
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

6.  HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape.

Authors:  S Abigail Smith; Charles Wood; John T West
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.